Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.

STATEMENT OF NEED

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to considerable advances in treatment, the rate of relapse remains high (ASCO, 2021; Samra et al, 2020). One reason for this is that older patients are often unable to tolerate curative therapy, leading to a lack of effective therapeutic options andless-than-optimal outcomes (Aldoss et al, 2019). In addition, variables such as comorbidities and cytogenic disease features make the selection of appropriate treatment difficult. Therefore, it is essential that the multidisciplinary team have a comprehensive understanding of emerging efficacy and safety data regarding novel therapeutic strategies. In this activity, Amir Fathi, MD, will update clinicians on strategies for developing individualized management plans in order to maximize treatment tolerability and improve outcomes for their patients with ALL.

TARGET AUDIENCE

Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Discuss predictive and prognostic markers that can individualize treatment selection for patients with B-cell ALL
Assess emerging efficacy and safety data on novel therapeutic strategies for B-cell ALL
Evaluate strategies to optimize the safety and tolerability of novel therapies for B-cell ALL